- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04912180
Apple Respiratory Study (ARS)
July 12, 2021 updated by: Apple Inc.
Apple Respiratory Study: A Prospective Study of Apple Watch-based Detection of Respiratory Viral Illness in Greater Seattle, WA
The Apple Respiratory Study, a collaboration between researchers at Apple Inc. (the "Study Sponsor" or "Sponsor") and the Seattle Flu Study team at the University of Washington (UW) (the "UW Study Team"), is a prospective, longitudinal cohort, low risk Study to collect certain data from Apple Watch and iPhone to determine whether such data can detect physiologic and non-physiologic changes in individuals associated with respiratory illnesses due to influenza, SARS-CoV-2 and other respiratory pathogens (the "Study").
Study Overview
Status
Terminated
Detailed Description
Initial Screening and Study enrollment will begin in 2021 among adults residing in the Greater Seattle area.
Participants will be recruited and driven to the online Study Website managed by UW.
If determined to be eligible following completion of the Prescreen Consent and an initial eligibility assessment via REDCap, potential participants will be asked to review and, if interested in participation, to complete the Main Study Consent via REDCap, as well as to engage in enrollment procedures across both REDCap and the Apple Research app.
Redcap will be used for prescreening, enrollment survey, and kit activation survey.
Participants will use the Apple Research app to complete onboarding surveys, weekly symptom surveys, illness follow-up surveys, and monthly lifestyle surveys.
These surveys will help the investigators learn about onset of respiratory symptoms as well as sick contacts, flu and/or COVID-19 vaccination and risk factors for illness.
Participants will also receive an Apple Watch to capture certain sensor data-which, along with iPhone sensor data, will be correlated with symptom onset and symptom trajectory.
If a participant experiences an acute respiratory illness (ARI), defined as at least one respiratory symptom for at least 24 hours, that individual will be asked to complete a symptom onset survey and self-collect an anterior nasal swab, which will be sent to UW Laboratory Medicine for analysis.
Participants will be able to access their COVID swab test results using a secure web portal.
Additionally, individuals who test positive or inconclusive for SARS-CoV-2 will be notified via phone by the UW Study Team and given instructions as defined by and in accordance with state, local, and national public health guidance.
Study Type
Observational
Enrollment (Actual)
108
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- University of Washington
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The Study aims to enroll up to 1000 adults.
We estimate that we will detect approximately 70 laboratory confirmed influenza cases and 40 laboratory confirmed SARS-CoV-2 cases based on estimated event rate incidences.
Description
Inclusion Criteria:
To participate in this Study, individuals must:
- Have access to an iPhone 6s or later with compatible iOS as defined by the Apple App Store.
- Have regular and reliable internet access
- Be willing to comply with all Study procedures, including regular use of the Apple Watch (daytime and nighttime), complete the REDCap and Apple Research app surveys, share data from required Apple Watch and iPhone sensors, and perform self-collected nasal swabs
- Be able to read and comprehend English
- Be able to provide informed consent without the use of a legally authorized representative
- Have a permanent mailing address in the greater Seattle area where Study materials can be mailed
- Be at least 22 years old at the time of consent
Exclusion Criteria:
To participate in this Study, individuals must not:
- Have previously tested positive for SARS-CoV-2 via PCR or antibody test
- Currently be enrolled in University of Washington Husky Coronavirus Testing, Household Observation Study, or any other Seattle Flu Study sub-Study
- Have received any vaccine for COVID-19 or have an upcoming appointment for at least one dose of any COVID-19 vaccine prior to Study consent
Individuals also may be excluded from the Study once target participant counts have been achieved for certain demographics, comorbidity groups, and/or residence based on zip code
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Symptomatic individuals that self-report ARI and have a laboratory-confirmed positive test for SARS-CoV-2 and/or influenza within 72 hours
Time Frame: Up to 6 months
|
Proportion of symptomatic individuals that self-report ARI and have a laboratory-confirmed positive test for SARS-CoV-2 and/or influenza by self-swab within 72 hours of symptom onset.
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Self-report ARI and positive test for SARS-CoV-2 and/or influenza within 7 days
Time Frame: Up to 6 months
|
Proportion of symptomatic individuals that self-report ARI and have a laboratory-confirmed positive test for SARS-CoV-2 and/or influenza by self-swab within 7 days of symptom onset.
|
Up to 6 months
|
Self-report ARI and test positive for other ARI within 7 days of symptom onset
Time Frame: Up to 6 months
|
Proportion of symptomatic individuals that self-report ARI and test positive for another respiratory pathogen by self-swab within 7 days of symptom onset
|
Up to 6 months
|
Onset of ARI event
Time Frame: Up to 6 months
|
Onset of ARI event defined as date and time of first self-reported symptoms (Day 0)
|
Up to 6 months
|
Hand washing Sessions
Time Frame: Up to 6 months
|
Completed hand washing sessions per week as detected by Apple Watch
|
Up to 6 months
|
Measure of Heart Rate
Time Frame: Up to 6 months
|
Measure of Heart Rate in Heart Beats per minute
|
Up to 6 months
|
Measure of Heart Rate Variability
Time Frame: Up to 6 months
|
Measure of Heart Rate Variability in the standard deviation in the time interval between heart beats in milliseconds over variable periods of time.
|
Up to 6 months
|
Measure of Blood Oxygen
Time Frame: Up to 6 months
|
Measure of Blood oxygen or oxygen saturation -percentage of hemoglobin in your red blood cells carrying oxygen (taken from Apple Watch)
|
Up to 6 months
|
Nasal swab sample that returns with no pathogens (viral and bacterial) on the panel
Time Frame: Up to 6 months
|
Pathogen-negative ARI (pathogen not detected by laboratory testing; "pathogen negative ARI" could be due to chronic respiratory diseases, viral clearance, or inadequate sample collection)
|
Up to 6 months
|
RNaseP and viral CRT values
Time Frame: Up to 6 months
|
RNaseP and viral CRT values for laboratory-confirmed virus positive ARI episodes
|
Up to 6 months
|
Duration of viral shedding and viral loads
Time Frame: Up to 6 months
|
Duration of viral shedding and viral loads in COVID-positive patients as assessed by four swabs collected over two weeks of follow-up
|
Up to 6 months
|
ECG Reports
Time Frame: Up to 6 months
|
Wrist-based Electrocardiogram (ECG) from smart watch containing time-series representation of the measured voltage corresponding to heart function over 30 second measurement periods.
|
Up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Helen Chu, MD, MPH, University of Washington
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 6, 2021
Primary Completion (Actual)
June 9, 2021
Study Completion (Actual)
June 9, 2021
Study Registration Dates
First Submitted
May 4, 2021
First Submitted That Met QC Criteria
May 28, 2021
First Posted (Actual)
June 3, 2021
Study Record Updates
Last Update Posted (Actual)
July 14, 2021
Last Update Submitted That Met QC Criteria
July 12, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00050502
- STUDY00011439/ ARS-2020-001 (Other Identifier: University of Washington Human Subjects Division)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The individual study data will not be shared beyond the investigative team, and only available to the sponsor in coded form.
These details are outlined in the study protocol.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronavirus Infection
-
The University of Hong KongHospital Authority, Hong KongCompletedNovel Coronavirus InfectionHong Kong
-
Affiliated Hospital to Academy of Military Medical...Beijing 302 HospitalUnknownNovel Coronavirus Infection PneumoniaChina
-
ProgenaBiomeDSCS CRORecruitingCOVID-19 | Coronavirus Infection | COVID | Corona Virus Infection | Coronavirus | Sars-CoV2 | Coronavirus-19 | Coronavirus 19United States
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
Concern GRANITSamara State Medical UniversityCompletedCoronavirus Infection COVID-19Russian Federation
-
D'Or Institute for Research and EducationUnknown
-
Chelsea and Westminster NHS Foundation TrustUnknownCOVID-19 | COVID-19 Infection | 2019 Novel Coronavirus InfectionUnited Kingdom
-
Institut National de la Santé Et de la Recherche...Recruiting
-
Kansas City Heart Rhythm InstituteTerminated
-
Universidade Federal de Sao CarlosTerminatedCoronavirus InfectionBrazil